ShangPharma Innovation and Icahn School of Medicine at Mount Sinai Forge Translational Research Collaboration
SOUTH SAN FRANCISCO, California and NEW YORK, Jan. 16, 2017 — ShangPharma Innovation Inc., a global venture capital firm focused on biomedical R&D therapeutics and technologies, and Icahn School of Medicine at Mount Sinai (ISMMS) have entered into a multi-year strategic collaboration to accelerate the development of novel early-stage therapeutics.
Under the terms of the agreement, ShangPharma Innovation will provide funding and preclinical research support to further ISMMS’s objectives of validating drug targets and establishing programs to discover new therapies. ShangPharma and Mount Sinai will share in the future value created through the collaboration.
“We are proud to be aligned with the Icahn School of Medicine at Mount Sinai and its legacy of achieving significant breakthroughs across the spectrum of biomedical research,” said Walter H. Moos, PhD, CEO of ShangPharma Innovation. “This represents a major milestone for ShangPharma Innovation as we push forward with innovation-minded collaborations that translate early-stage science into novel treatments for patients.”
The collaboration agreement anticipates that ShangPharma Innovation will provide multiple years of R&D funding at ISMMS’s clinical institutes in New York. ShangPharma Innovation also will provide additional support in the form of research services from Shanghai ChemPartner Co. Ltd., a full-service life science CRO with over 15 years of pharmaceutical research experience.
“This partnership was fueled by the groundbreaking technologies from innovators here at Mount Sinai. Our expertise in commercially-relevant translational research, coupled with ShangPharma Innovation’s drug development capabilities will advance much needed medicines to patients worldwide,” said Erik Lium, PhD, Senior Vice President of Mount Sinai Innovation Partners.
About ShangPharma Innovation Inc.
ShangPharma Innovation Inc. is a healthcare venture capital firm that accelerates and facilitates pharmaceutical discovery and development. With a focus on therapeutics and technology platforms, ShangPharma Innovation offers funding, incubator space and other support to its ecosystem of portfolio companies, collaborators and partners. This includes sponsoring biotech start-ups and proof-of-concept research at major academic and medical centers and research institutes. ShangPharma Innovation maintains active research partnerships with University of California, San Francisco; The Scripps Research Institute in La Jolla, Calif.; and the nonprofit research center SRI International. For more information, see http://www.spiivc.com.
About Mount Sinai Health System
The Mount Sinai Health System is New York City’s largest integrated delivery system, encompassing seven hospital campuses, a leading medical school and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai’s vision is to produce the safest care, the highest quality, the highest satisfaction, the best access and the best value of any health system in the nation. The Mount Sinai Hospital is ranked as one of the nation’s top 20 hospitals in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Geriatrics, Nephrology, and Neurology/Neurosurgery, and is in the top 50 in four other specialties in the 2017-2018 “Best Hospitals” issue of U.S. News & World Report. Mount Sinai’s Kravis Children’s Hospital also is ranked in seven out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 12th nationally for Ophthalmology, while Mount Sinai Beth Israel, Mount Sinai St. Luke’s and Mount Sinai West are ranked regionally. For more information, visit http://www.mountsinai.org/, or find Mount Sinai on Facebook, Twitter and YouTube.
About Mount Sinai Innovation Partners (MSIP)
MSIP is responsible for driving the real-world application and commercialization of Mount Sinai discoveries and inventions, and the development of research partnerships with industry. Our aim is to translate discoveries and inventions into health care products and services that benefit patients and society. MSIP is accountable for the full spectrum of commercialization activities required to bring Mount Sinai inventions to life. These activities include evaluating, patenting, marketing and licensing new technologies, building research collaborations and partnerships with commercial and nonprofit entities, material transfer and confidentiality, coaching innovators to advance commercially-relevant translational discoveries, and actively fostering an ecosystem of entrepreneurship within the Mount Sinai research and health system communities. For more information, visit http://www.ip.mountsinai.org.
Partners HealthCare raises $171 million to invest in early-stage life science companies
Boston, Massachusetts., Nov. 8, 2017 – Exclusively dedicated to the development of breakthrough technologies that help patients and the state’s innovation economy.
Partners HealthCare System announced today the closing of $171.1 million in capital to invest in early- stage life sciences companies, which are a critical segment of the state’s innovation economy.
The funds raised include $66.1 million in outside capital for Partners Innovation Fund II and a $105 million commitment from Partners institutions to Partners Innovation Fund. The capital commitments to Partners Innovation Fund include two $50 million commitments each from The Brigham and Women’s Hospital and Massachusetts General Hospital. The investment strategy will focus exclusively on medical innovations created in the Partners system.
Partners Innovation Fund was launched in 2008 by Partners HealthCare with $35 million in capital. Since its inception, Partners Innovation Fund has invested in 32 companies. Notable successes include CoStim Pharmaceuticals, Inc., a pioneer in next generation immuno-oncology drugs (acquired by Novartis Inc.); Adheron, a company developing potential treatments for a variety of inflammatory and autoimmune diseases such as rheumatoid arthritis and fibrotic diseases (acquired by Roche); and Editas Medicine Inc. (NASDAQ: EDIT), a market leader in revolutionary CRISPR gene editing technology. Partners Innovation Fund will continue to execute the fund’s investment strategy of launching and backing innovative healthcare companies that address unmet medical needs and improve healthcare delivery. Investments will be diversified across key industry sectors, including therapeutics, diagnostics, health care IT and medical devices. The fund will leverage its position within Partners’ pre-eminent research and healthcare provider ecosystem to identify leading-edge technologies invented by investigators.
Partners Innovation Fund II is anchored by several pharmaceutical industry leaders, including Astellas Pharma Inc., Eli Lilly and Company, ShangPharma Corporation, and Simcere Pharmaceutical Group.
“We are delighted to have the support of global market-leading strategic investors to leverage Partners intellectual assets, scientific talent, and clinical expertise,” said Roger Kitterman, Vice President of Partners Innovation.
“Bringing discoveries, inventions and innovations from our world-class research community to the market benefits patients, always our primary focus, as well as the life sciences sector so important to the state’s economic future,” said Anne Klibanski, Chief Academic Officer of Partners HealthCare. “This collaboration underscores Partners’ commitment to promote the commercialization of inventions and discoveries originating from the Partners community and to translate those discoveries into treatments for patients.”
Partners HealthCare is a Boston-based integrated health system founded by Brigham and Women’s Hospital and Massachusetts General Hospital. In addition to its two academic medical centers, the Partners system includes community and specialty hospitals, a managed care organization, community health centers, a physician network, home health and long-term care services, and other health-related entities. Partners is the largest academic research organization in the United States and a principal teaching affiliate of Harvard Medical School. Partners HealthCare is a non-profit organization.
ShangPharma Innovation Names Two Executives-In-Residence
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2017 – ShangPharma Innovation Inc., a global venture capital firm and innovation incubator focused on biomedical R&D therapeutics and technologies, announced the appointment of Dirk G. Brockstedt, Ph.D., and Benson Tsang, MBA, to its Executive-In-Residence (EIR) team.
ShangPharma Innovation’s esteemed EIR team provides the organization with expert advice on business, financial, scientific and strategic development of important biomedical initiatives, including the identification and assessment of novel opportunities for early-stage equity investments and promising incubator tenants for ShangPharma Innovation’s South San Francisco facility. EIRs also participate in the negotiation and management of collaborations, licenses and partnerships.
“Dirk and Benson collectively bring a deep level of scientific and financial acumen to our EIR team,” said Dr. Walter H. Moos, CEO of ShangPharma Innovation. “Together with their EIR colleagues, we anticipate they will play a vital role in our mission to accelerate and facilitate pharmaceutical R&D, as we continue to build a robust biotechnology innovation and investment practice.”
Dr. Brockstedt is executive vice president of research and development for Aduro Biotech, an immunotherapy company. Prior to joining Aduro in 2009, he held various positions at Cerus Corp., where he was a foundational member of the original immunotherapy group. Dr. Brockstedt previously served as a scientist at Aventis, where he developed novel cancer therapies. He has co-authored 40 scientific papers and is a named inventor on five issued patents and several pending applications. He holds a degree in microbiology from the University of Kiel in Germanyand completed doctoral and postdoctoral work at Stanford University and the Stanford School of Medicine.
Benson Tsang brings nearly 30 years of financial and general management experience to ShangPharma Innovation. He has served as an independent director of ShangPharma Corp. and previously held the role of chief financial officer at WuXi Pharmatech Inc., where he was instrumental in the company’s successful IPO in 2007. Benson also held senior positions at ATA Inc., PCCW Ltd., Imation Corp., Coopers & Lybrand and Deloitte. He is a member of the Canadian Institute of Chartered Accountants and the Hong Kong Institute of Certified Public Accountants. Benson also holds a Bachelor of Commerce degree and an MBA from McMaster University in Ontario, Canada.
About ShangPharma Innovation Inc.
ShangPharma Innovation Inc. is a novel healthcare venture capital firm founded in the U.S. in 2016. ShangPharma Innovation accelerates and facilitates pharmaceutical discovery and development – focusing on therapeutics and technology platforms – and offers funding, incubator space, and other support to its ecosystem of portfolio companies, collaborators, and partners. This includes sponsoring biotech start-ups and proof-of-concept research at major academic and medical centers and research institutes. For more information, see http://www.spiivc.com.
Strategic partnership to target Alzheimer’s disease and other neurodegenerative and inflammatory conditions
MENLO PARK, Calif., October 9, 2017 – ShangPharma Innovation Inc. (SPII) and SRI International today announced a strategic collaboration to accelerate the development of innovative pharmaceuticals targeting neuroinflammation as a treatment for Alzheimer’s and other diseases.
This collaboration with SRI marks another milestone for SPII in its effort to enable a series of promising therapeutic projects at major institutions with a history of innovative contributions to biomedical research. Internationally recognized for its expertise through all stages of drug discovery and development, SRI Biosciences, a division of SRI International, has a well-established drug pipeline, having advanced four if its own drugs to market and more than 100 partner medicines to clinical trials.
“It has been said that Alzheimer’s disease could bankrupt the nation by 2050 in the absence of major advances,” said Walter H. Moos, Ph.D., CEO of SPII and retired president of SRI Biosciences. “I am exceptionally pleased to work again with outstanding colleagues at SRI to tackle such an important problem.”
“We are delighted to join with SPII to address one of the most debilitating diseases of our time,” said Nathan Collins, Ph.D., vice president of SRI Biosciences. “At a time when new approaches are desperately needed, SRI’s proven track record in target discovery and validation, combined with SRI’s and SPII’s joint expertise in accelerating drug discovery, will help to create new treatments for Alzheimer’s and other diseases where inflammation is an underlying issue.”
“As a non-profit, SRI deeply values initiatives and partnerships that have the potential to make the world healthier, safer, and more productive,” said Manish Kothari, Ph.D., president of SRI Ventures. “This initiative exemplifies those core values, and highlights SRI’s willingness to invest in challenging projects with high impact potential.”
Under the terms of the agreement, SPII and SRI will apply state-of-the-art methods to advance novel enzyme inhibitors that target brain inflammation and will seek third party licensees for the compounds. SPII will work with preferred partners, including its affiliate, ChemPartner, to provide discovery and development capabilities to SPII and SRI collaborative projects. The organizations will design, screen, carry out mechanistic studies, and ultimately progress novel drug candidates toward clinical trials. SPII and SRI will share in the business success of the program.
About ShangPharma Innovation
ShangPharma Innovation Inc., is a novel healthcare venture capital firm founded in the US in 2016. ShangPharma Innovation accelerates and facilitates pharmaceutical discovery and development – focusing on therapeutics and technology platforms – and offers funding, incubator space, and other support to its ecosystem of portfolio companies, collaborators, and partners. This includes sponsoring biotech start-ups and proof-of-concept research at major academic and medical centers and research institutes. For more information, see http://www.spiivc.com.
About SRI Biosciences
SRI Biosciences, a division of SRI International, creates innovations in the life sciences through integration of basic biomedical research with drug and diagnostics discovery and preclinical and clinical development. SRI International creates world-changing solutions making people safer, healthier, and more productive. SRI, a research center headquartered in Menlo Park, California, works primarily in advanced technology and systems, biosciences, computing, and education. SRI brings its innovations to the marketplace through technology licensing, spin-off ventures and new product solutions.
Shanghai ChemPartner Co. Ltd., along with its subsidiary entities, is a leading research organization providing high-quality and cost-effective contract research services for the biopharmaceutical industry. ChemPartner offers integrated services across the drug discovery and development process to pharmaceutical and biotechnology companies worldwide. ChemPartner’s dedication to life science is seen through its broad range of services, from discovery biologics, discovery chemistry, discovery biology, and preclinical development through pharmaceutical development and manufacturing services for small molecules and biologics. For more information, see http://www.chempartner.com.
ShangPharma Innovation and the University of California San Francisco Announce Strategic Research Collaboration
— New innovation group and leading medical center partner on novel approach to advance therapies across the often
overlooked early-stage gap in biomedical research —
SOUTH SAN FRANCISCO and SAN FRANCISCO, Calif., July 11, 2017 – In a new collaboration, ShangPharma Innovation, Inc. (SPII) is providing funding and other support to scientists at UC San Francisco (UCSF) to accelerate the development of promising life science inventions.
The partnership helps advance a major new initiative at UCSF to bridge academic research with industrial development. Part of this effort, which SPII will support, involves backing preclinical research to validate drug targets and to develop programs to discover new drugs. Drugs that UCSF and SPII determine to be promising in preclinical studies can then be readied for clinical trials to demonstrate safety and efficacy in patients.
The collaboration agreement anticipates that SPII will provide several years of funding to carry out R&D in UCSF laboratories. SPII also will commit to spend additional amounts each year during the term of the collaboration to purchase Contract Research Organization (CRO) services in support of the projects being conducted by SPII and UCSF. CRO services will be provided by Shanghai ChemPartner Co. Ltd. (ChemPartner). SPII and UCSF will share in future value created through this innovative partnership.
“When the proper bridges to fundamental research are built, important new medicines reach the marketplace, saving and improving lives around the world,” said Walter H. Moos, PhD, CEO of SPII and adjunct professor of pharmaceutical chemistry at UCSF. “We have only just begun to scratch the surface of what’s possible when academia and early-stage investors come together to advance novel discoveries. We look forward to enabling biomedical innovation across all borders and disciplines.”
Cathy Tralau-Stewart, PhD, interim director of UCSF’s Catalyst Program and adjunct associate professor of bioengineering and therapeutics at UCSF, said, “The translation of early research into novel therapeutics for patients requires a wide range of expertise and capabilities. This collaboration will give UCSF access to the broad range of expertise and services required and will enable the translation of more UCSF discoveries to product opportunities with real potential benefit for patients. This is an important collaboration, and we look forward to working closely with the ShangPharma and ChemPartner teams.”
About UCSF: UC San Francisco (UCSF) is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. It includes top-ranked graduate schools of dentistry, medicine, nursing and pharmacy; a graduate division with nationally renowned programs in basic, biomedical, translational and population sciences; and a preeminent biomedical research enterprise. It also includes UCSF Health, which comprises three top-ranked hospitals, UCSF Medical Center and UCSF Benioff Children’s Hospitals in San Francisco and Oakland, and other partner and affiliated hospitals and healthcare providers throughout the Bay Area.
About ShangPharma: Innovation ShangPharma Innovation, Inc., founded in the US in 2016, facilitates and accelerates drug discovery, focusing on both therapeutics and technology platforms, and offers funding, incubator space, and other support to its ecosystem of collaborators, partners, and tenants. This includes sponsoring proof-of-concept research at major academic and medical centers, research institutes, and seed-stage start-ups, leading to industry collaborations and venture capital financing. ShangPharma Innovation and ChemPartner are affiliates and preferred partners. Services will be provided predominantly or solely by ChemPartner at their standard commercial rates. For more information, see https://www.shangpharmainnovation.com.
World-class research institute and new innovation center partner to accelerate early translational research
La Jolla, California (June 8, 2017) – The Scripps Research Institute (TSRI) and ShangPharma Innovation, Inc. (SPII) today announced a strategic collaboration to accelerate the development of innovative drug candidates through scientific collaboration, a services relationship with Shanghai ChemPartner Co. Ltd. (ChemPartner), and sponsored research at TSRI and its drug discovery affiliate, California Institute for Biomedical Research (Calibr). The parties aim to leverage the drug discovery pipeline, expertise, and momentum emerging from the TSRI and Calibr affiliation announced late last year.
SPII facilitates and accelerates drug discovery by offering funding, incubator space, and other essential support to its collaborators. The partnership with TSRI marks a major new initiative for SPII to enable its mission to support therapeutic research at the earliest stages with the ultimate goal of getting innovative new treatments to patients.
Under the terms of the collaboration, institute scientists will put forth translational research projects to a joint committee comprising drug discovery experts across TSRI, Calibr, and SPII. In turn, SPII will contribute cash and in-kind services totaling up to $15 million over an initial term of three years. TSRI and Calibr will retain control over assets resulting from the collaboration, with SPII receiving a significant share of future value.
“We are delighted to partner with an experienced group that has complementary infrastructure and resources,” said Peter G. Schultz, Ph.D., President of TSRI and Calibr. “This new initiative allows us to further accelerate our mission of creating new medicines for unmet needs in a nimble partnership structure designed to mature the programs before out-licensing, creating significant value for patients as well as for the institute.”
“Biomedical R&D is one of the most challenging areas of science across all disciplines and industries. Strategic partnerships often drive success in making the impossible possible. That is exactly what we plan to do in this alliance with TSRI and Calibr,” stated Walter H. Moos, Ph.D., CEO of SPII. “Unlocking the potential of top investigators at TSRI and Calibr to advance novel therapies and ultimately to save and improve lives is our joint goal.”
About The Scripps Research Institute
The Scripps Research Institute (TSRI) is one of the world’s largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs more than 2,500 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including two Nobel laureates and 20 members of the National Academies of Science, Engineering or Medicine—work toward their next discoveries. The institute’s graduate program, which awards doctoral degrees in biology and chemistry, ranks among the top ten of its kind in the nation. In October 2016, TSRI announced a strategic affiliation with the California Institute for Biomedical Research (Calibr), representing a renewed commitment to the discovery and development of new medicines to address unmet medical needs. For more information, see http://www.scripps.edu/ .
About ShangPharma Innovation
ShangPharma Innovation Inc., founded in the US in 2016, facilitates and accelerates drug discovery, focusing on both therapeutics and technology platforms, and offers funding, incubator space, and other support to its ecosystem of collaborators, partners, and tenants. This includes sponsoring proof-of-concept research at academic and major medical centers, research institutes, and seed-stage start-ups, leading to industry collaborations and venture capital financing. ShangPharma Innovation and ChemPartner are affiliates and preferred partners. Services will be provided predominantly or solely by ChemPartner at their standard commercial rates.
Shanghai ChemPartner Co. Ltd., along with its subsidiary entities, is a leading research organization providing high-quality and cost-effective contract research services for the biopharmaceutical industry. ChemPartner offers integrated services across the drug discovery and development process to pharmaceutical and biotechnology companies worldwide. ChemPartner’s dedication to life science is seen through its broad range of services, from discovery biologics, discovery chemistry, discovery biology, and preclinical development through pharmaceutical development and manufacturing services for small molecules and biologics.
ShangPharma Innovation, Inc. (SPII) announced the addition of David Spellmeyer, PhD and Robert Lutz, PhD to its Executive-In-Residence (EIR) team.
The EIR team provides SPII with expert advice on a wide range of business, scientific, and strategic topics. This includes the identification and assessment of novel opportunities for early-stage equity investments and new venture incubator tenants at SPII’s San Francisco Bay Area facility. Drs. Spellmeyer and Lutz will also participate in the negotiation and management of collaborations, licenses, and partnerships.
Dr. Spellmeyer is a biotechnology executive with 25 years of broad experience in the life sciences industry. He heads Interlaken Associates where he advises early-stage companies and investors on corporate and technical strategy, product development, commercialization, and funding. He previously served as CTO & CIO at Nodality and in research leadership roles at both large and small companies. Dr. Spellmeyer received his BS in computer science and chemistry from Purdue University and his PhD in theoretical organic chemistry from UCLA. He completed postdoctoral training in pharmaceutical chemistry at UCSF, where he is an adjunct Associate Professor.
Dr. Lutz founded Crescendo BioPharma Consulting and provides strategic, tactical, and operational expertise to help meet the needs of emerging biotechnology and pharmaceutical companies worldwide. He focuses on guiding transitions from discovery to clinical proof-of-concept. Previously, for more than 20 years, he was employed at Immunogen, Inc., last holding the position of Vice President, Translational Research and Development. Dr. Lutz received his BS and PhD in biochemistry from the University of New Hampshire and Brandeis University, respectively, and was a postdoctoral fellow at the Eleanor Roosevelt Institute.
“We are pleased to add Dr. Spellmeyer and Dr. Lutz to our EIR ranks. Having access to such experienced and successful entrepreneurs will greatly benefit our innovation practice at all stages of biomedical R&D,” said Dr. Walter H. Moos, CEO of SPII.
ShangPharma Innovation (SPI) today announced the appointment of Mohamad Moghadam-Tabrizi to the position of Senior Vice President, Business Development.
Mr. Tabrizi previously served in senior and executive level positions in corporate business development at Nektar, investor relations and corporate communications at Depomed, healthcare investment banking at Needham, RBC Capital Markets, and Merrill Lynch, and as CFO at Alacritas (Omnicare). In these roles, Mohamad led numerous deals spanning the range of royalty monetization, out-licensing and in-licensing, manufacturing and supply, collaborations and partnerships, mergers and acquisitions, and public and private financings including roadshows and venture investments.
“We are very pleased to welcome Mohamad to ShangPharma Innovation. He is a highly successful professional with broad transaction expertise in all aspects of business and corporate development in the biopharmaceutical industry—financial, investor, licensing, strategic, and more,” said Walter H. Moos, CEO of SPI.
Earlier in his career, Mohamad was a researcher at the Howard Hughes Medical Institute, Stanford University Medical School, and Systemix. He received his undergraduate and graduate training in genetics and biological sciences at the University of California Davis and Stanford University and an MBA from Cornell University.
Mohamad will aid in the achievement of key objectives at SPI which include facilitating and accelerating drug discovery with a focus on therapeutics and platform technologies, and also offering funding, other support, and incubator space to entrepreneurial partners. These partnerships include proof-of-concept research at academic and major medical centers, research institutes, and early-stage start-ups with the goal of achieving industry collaborations and/or venture capital financing.
ShangPharma Innovation (SPI) announced the appointment of Peter DiLaura, Ravi Kiron MBA PhD, Krishna Kodukula PhD, and Robert Wild PhD to its founding Executive-In-Residence (EIR) team.
The EIR team will provide ShangPharma Innovation with expert advice on business, scientific, and strategic development of biomedical initiatives, including the identification and assessment of novel opportunities for early-stage equity investments and new venture incubator tenants at SPI’s South San Francisco facility. They will also participate in the negotiation and management of collaborations, licenses, and partnerships.
Mr. DiLaura is a life sciences executive based in San Francisco, CA. He currently advises a number of biotechnology and pharmaceutical companies and investors, and was CEO of Second Genome, a pioneering microbiome therapeutics company, from seed financing through clinical development. Previously, Mr. DiLaura held a range of executive roles in the systems biology company Ingenuity Systems (Qiagen), with responsibility for commercial operations, sales and marketing, product strategy, and corporate development. He was also a Consultant at The Wilkerson Group, providing strategic consulting to biotech, pharma, medical device, and diagnostic companies and investors. He holds a BS in Economics from The Wharton School at the University of Pennsylvania.
Dr. Kiron, based in San Jose, CA, is an experienced pharma/biotech executive with decades of experience from early drug discovery through late-stage clinical development, intellectual property, regulatory strategy and product commercialization. Dr. Kiron has consulted for dozens of life sciences companies, founded and led multiple new ventures, was an EIR at SRI Ventures, and serves currently on many company and non-profit boards. Dr. Kiron has also held operational & executive roles at Pfizer and J&J/Alza in cardiovascular and oncology R&D and strategic business development. He has a wide breadth of hands-on experience negotiating and executing partnerships, mergers and acquisitions (WLA, PHA, biotechs), and has extensive global networks. Previously, he was a faculty member at Cornell University Medical College and at University of Rhode Island. Dr. Kiron earned BS and MS degrees from the University of Mumbai, a PhD from the Indian Institute of Science, and an MBA from Rensselaer Polytechnic Institute.
Dr. Kodukula, based in Princeton, NJ, is a pharmaceutical professional with decades of experience in the industry and non-profit sectors, in research and business roles. Previously, he was Executive Director, Strategic Development at SRI Biosciences (Stanford Research Institute); Site Head and Founder of SRI Shenandoah Valley; Distinguished Member of Technical Staff at Sarnoff Corporation; in leadership/founder roles at Pyxis Technology Solutions and Small Molecule Therapeutics; and in research scientist positions at Bristol-Myers Squibb and Hoffmann-LaRoche. Dr. Kodukula has served on many boards, including several gubernatorial appointments, and has been listed as one of 50 most influential business leaders in Virginia. Dr. Kodukula received undergraduate and graduate degrees at Andhra and Utkal Universities in India, and did postdoctoral work at the Indian Institute of Science and Roche Institute of Molecular Biology.
Dr. Wild, based in San Diego, CA, is a seasoned R&D executive with almost 20 years of broad biotech/pharma industry experience in drug discovery and development, spanning both small molecules and biologics. He currently advises a number of biotechnology and pharmaceutical companies and investors. Dr. Wild has contributed to the advancement of numerous clinical development candidates, including four FDA-approved oncology therapeutics. Dr. Wild previously served as CSO and Senior VP Research at Ignyta; CSO Oncology Research at Eli Lilly; Senior Director at OSI (Astellas); and as a research scientist at Bristol-Myers Squibb and Sugen. He received his undergraduate and graduate degrees at the University of Minnesota.
Dr. Walter H. Moos, CEO of ShangPharma Innovation, commented, “Our EIR colleagues greatly strengthen our global leadership capabilities. With their successful entrepreneurial, biotech and pharma experience, and global executive-level relationships, they will help us expand and manage our innovation practice in all phases of biomedical R&D. We anticipate naming additional leaders to our team in the near future.”
ShangPharma Innovation facilitates and accelerates drug discovery, focusing on both therapeutics and technology platforms, and offers funding, incubator space, and other support to its collaborators, partners, and tenants. This includes sponsoring proof-of-concept research at academic and major medical centers, research institutes, and seed-stage start-ups, leading to industry collaborations and venture capital financing.
ShangPharma Innovation, a newly incorporated division of the ShangPharma Group, announced today the appointment of Walter H. Moos, PhD, to the position of Chief Executive Officer.
Dr. Moos has served in executive roles in pharmaceutical and biotechnology companies and nonprofit research institutes since the 1980s. He has served on numerous boards and as an advisor to government, nonprofit, and for-profit organizations, and he has held faculty positions at several major universities. Dr. Moos has co-founded several scientific journals, co-authored or edited multiple books, and has published and patented widely.
Michael Hui, Chairman of ShangPharma stated, “Walter is an outstanding addition to our global leadership team. He will help us grow our innovation practice, which encompasses early-stage equity investments of cash and in-kind services, new venture incubation, and more. His vast experience and contributions to all phases of biomedical R&D, from research to marketed products, made him the categorical choice as CEO at ShangPharma Innovation.”
ShangPharma Innovation facilitates and accelerates drug discovery, focusing on chemical and biological therapeutics and novel technologies, and offers funding, other support, and incubator space to its entrepreneurial partners. These partnerships include proof-of-concept research at academic and major medical centers, research institutes, and seed-stage start-ups, leading to industry collaborations and venture capital financing.
“With groundbreaking research, miracles do happen, and important new drugs reach the marketplace, saving countless lives, returning capital to investors, and triggering re-investment in more innovation,” said Dr. Moos. “We have only just begun to scratch the surface of what’s possible when drug hunters come together in newly enabled R&D ecosystems. We look forward to what ShangPharma Innovation can catalyze in global health R&D across all borders and disciplines.”